IDEAYA Biosciences
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING4
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.9 months). See all sponsors →
Open IDEAYA Biosciences on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IDE196 NCT05987332 |
P2/3 | Active, not recruiting | Metastatic Uveal Melanoma | 420 | 2027-01-15 |
| IDE196 NCT03947385 |
P1/2 | Recruiting | Metastatic Uveal Melanoma; Cutaneous Melanoma | 336 | 2027-01-29 (+61 mo) |
| Darovasertib NCT05907954 |
P2 | Active, not recruiting | Uveal Melanoma | 160 | 2027-04-30 (+15 mo) |
| IDE849 NCT07174583 |
P1/2 | Recruiting | Small-cell Lung Cancer; Neuroendocrine Carcinomas | 262 | 2029-07 (+2 mo) |
| Darovasertib NCT07015190 |
P3 | Recruiting | Uveal Melanoma | 520 | 2030-10 (+41 mo) |
| Darovasertib NCT07804186 |
P3 | Recruiting | Uveal Melanoma | 450 | 2034-03 |